文献速递银屑病与炎症性皮肤病

BAT2206与参照乌司奴单抗治疗中重度斑块状银屑病的随机III期对照研究

A randomized phase III study to compare efficacy and safety of BAT2206 (proposed ustekinumab biosimilar) with reference ustekinumab in patients with moderate to severe plaque psoriasis.
PubMed 文献 · J Am Acad Dermatol · 2024-11-24

本研究为随机、双盲、III期研究,纳入278例中重度斑块状银屑病患者,按1:1随机接受BAT2206(拟议乌司奴单抗生物类似药)或参照乌司奴单抗治疗。主要终点为第8周和第12周PASI评分较基线百分比变化,结果显示两组最小二乘均值差异的置信区间均完全落在预设等效界值内,安全性和药代动力学等次要终点也具可比性。

要点

  • BAT2206与参照乌司奴单抗在第8周和第12周PASI评分变化上达到等效。
  • 两组在安全性、药代动力学和免疫原性方面结果可比。
  • 本研究仅报告了28周初始治疗期(TP1)的结果。

核心结论

  • BAT2206与参照乌司奴单抗在疗效、安全性、药代动力学和免疫原性方面具有可比性。

研究设计与样本

  • 随机、双盲、III期研究,278例中重度斑块状银屑病患者按1:1随机接受BAT2206或参照乌司奴单抗治疗,依据基线体重给予45 mg或90 mg,直至第28周(TP1)。

主要发现

  • 第8周PASI评分较基线百分比变化的最小二乘均值差异(标准误)为0.964(1.8952),第12周为1.774(1.4912)。
  • 上述最小二乘均值差异的置信区间均完全落在预设等效界值内。

局限性

  • 因篇幅限制,本文仅描述TP1(28周初始治疗期)的结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: BAT2206 is a proposed biosimilar to reference ustekinumab (UST; Stelara). OBJECTIVES: To compare the efficacy and safety of BAT2206 with UST at 2 treatment periods, ie, a 28-week initial treatment period 1 (TP1) and a 24-week secondary TP2. This article describes the results of TP1. METHODS: In this randomized, double-blind, phase III study, adult patients with moderate to severe plaque psoriasis were randomized (1:1) to receive 45 or 90 mg of BAT2206 or UST until week 28 in TP1, depending on their baseline body weight. The primary end point was the percent change from baseline in Psoriasis Area and Severity Index score to week 8 or 12. The secondary end points included safety, pharmacokinetics, and immunogenicity parameters. RESULTS: In all, 278 patients were each randomized into the BAT2206 or UST groups. At weeks 8 and 12, the least squares mean difference (standard error) for percent change from baseline in Psoriasis Area and Severity Index score was 0.964 (1.8952) and 1.774 (1.4912), respectively, and the least squares mean difference confidence intervals all completely fell within the predefined equivalence margins. Comparable results were observed between the treatment groups for secondary end points. LIMITATIONS: Owing to the length limit, this article only described the findings from TP1. CONCLUSIONS: BAT2206 and UST were comparable in terms of efficacy, safety, pharmacokinetics, and immunogenicity.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Man X, Zaharieva K, Pulka G, et al. A randomized phase III study to compare efficacy and safety of BAT2206 (proposed ustekinumab biosimilar) with reference ustekinumab in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2024. PMID: 39592058. doi:10.1016/j.jaad.2024.10.104

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。